The polypeptide Tissue Factor Pathway Inhibitor (TFPI) and variants thereof can be advantageously stored in a form (e.g., a concentrated aqueous solution) that exhibits high stability and thereafter converted (e.g., by mixing with a diluent) into a form that is therapeutically effective (e.g., in the treatment of severe Community Acquired Pneumonia) when administered parenterally (e.g., intravenously) to patients. The separate storage of components of pharmaceutical compositions comprising TFPI and TFPI variants provides several important advantages. The components are generally a concentrated polypeptide solution and a diluent.